LONDON, GREATER LONDON, UNITED KINGDOM, January 22, 2025 /EINPresswire / -- What has been the historic growth trend in the abrysvo or arexvy global market and what is expected in the coming years?

FDA 2025 pulmonology drug alerts, including drug approvals/warnings, vaccine approvals, and medical device recalls/updates.

The prescribing information for two respiratory syncytial virus (RSV) vaccines will now include a warning for the increased ...

The prescribing information for Abrysvo ® (respiratory syncytial virus [RSV] vaccine) and Arexvy ® (RSV vaccine, adjuvanted) has been updated to include a new warning regarding the risk of ...

The estimated effectiveness of the respiratory syncytial virus (RSV) among older US veterans in the 2023-2024 respiratory ...

GlaxoSmithKline (GSK – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Graham Parry from ...

We recently published a list of 12 Undervalued Defensive Stocks for 2025. In this article, we are going to take a look at ...

Shares were also aided by a successful US and European launch of Arexvy, a respiratory syncytial virus (RSV) vaccine for older adults. Although risks around the Zantac litigation remain a concern ...

In its update posted this morning, GSK revealed that sales of its Arexvy vaccine came in at £1.24 billion ($1.57 billion) in 2023, including £529 million ($671 million) from the fourth quarter.

The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET ...

Abrysvo is currently under FDA review as a maternal vaccine and is Beyfortus’ closest rival after GSK stopped the development of Arexvy in this setting. SP0125, meanwhile, is an intranasal ...